Helus Pharma Secures US$195M Cash, Shows 35% Response in Phase 2a SPL026 Trial
Helus Pharma rebranded in January 2026 and holds US$195.1 million cash to advance its lead serotonergic agonist programs with over 350 filed patents through at least 2041. Its Phase 2a trial of SPL026 in treatment-resistant depression showed a mean MADRS reduction of 7.35, 35% response (p=0.023) and 29% remission versus 12% for placebo.
1. Federal Quota Expansion
The Drug Enforcement Administration raised its 2026 psilocybin production quota by 67%, widening supply for companies developing psychedelic therapies including Helus Pharma.
2. Rebranding and Intellectual Property
Helus Pharma rebranded in January 2026 (formerly Cybin) and holds over 350 filed patents with more than 100 granted, protecting its serotonergic agonist pipeline through at least 2041.
3. Positive Phase 2a Results
In a randomized, placebo-controlled trial of SPL026 in moderate-to-severe major depressive disorder, a single 21.5 mg dose achieved a mean MADRS reduction of 7.35 (p=0.023), 35% response (p=0.023) and 29% remission versus 12% for placebo, with effects lasting up to six months.
4. Cash Position and Upcoming Data
Helus reported US$195.1 million cash as of December 31, 2025, supporting advancement of HLP004 in Phase 2 for generalized anxiety disorder with topline data expected this quarter and two pivotal Phase 3 studies of HLP003 on track for Q4 2026 topline readouts.